

July 31, 2024

The Secretary Listing Department, BSE Limited, 1 <sup>st</sup> Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/ Madam,

**Sub: 1. Outcome of Board Meeting held on July 31, 2024, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**2. Unaudited financial results for the quarter ended June 30, 2024, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we wish to inform you that:

1. The Meeting of the Board of Directors commenced at 02:00 pm (IST) and concluded at 8:00 pm (IST).
2. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2024, together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as **Annexure-I**.
3. Publication of the results in the Newspaper is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. Based on recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company:
  - i. Appointed Mr. Maniedath Madhavan Nambiar (DIN: 01122411) as an Additional Director (Non-Executive Independent Director) of the Company with effect from July 31, 2024.
  - ii. Appointed Mr. Sunil Theckath Vasudevan (DIN: 00294130) as an Additional Director (Non-Executive Independent Director) of the Company with effect from July 31, 2024.
  - iii. Appointed Mr. Anoop Moopen (DIN: 02301362) as an Additional Director (Non-executive non - Independent Director) of the Company with effect from July 31, 2024.

- iv. Appointed Dr. Zeba Azad Moopen (DIN: 03604401) as an Additional Director (Non-executive non - Independent Director) of the Company with effect from July 31, 2024, subject to approval of the shareholders.

In compliance with Circular Number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13<sup>th</sup>,2023 pertaining to continuous disclosure requirements for Listed Entities under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed **Annexure II** for your records.

Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thank you,

For **Aster DM Healthcare Limited**

HEMISH  
PURUSHO  
TTAM

Digitally signed  
by HEMISH  
PURUSHOTTAM  
Date: 2024.07.31  
20:01:42 +05'30'

**Hemish Purushottam**

Company Secretary and Compliance Officer

M. No: A24331

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Aster DM Healthcare Limited** ("the Company"), which includes interim financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust"), for the quarter ended 30 June 2024 ("Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Unaudited Standalone Financial Results includes the interim financial information of the ESOP trust which have not been reviewed by its auditor whose interim financial information reflect total revenue of INR 19.04 for the quarter ended 30 June 2024, total net profit after tax of INR 17.18 crores for the quarter ended 30 June 2024 and total comprehensive income of INR 17.18 crores for the quarter ended 30 June 2024 as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Company.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration No. 008072S)  
**VIKAS**  
**BAGARIA**  
Digitally signed by  
VIKAS BAGARIA  
Date: 2024.07.31  
19:21:18 +05'30'  
**Vikas Bagaria**  
(Partner)  
(Membership No. 60408)  
(UDIN: 24060408BKFSMJ2734)

Place: Calicut, Kerala  
Date: 31 July 2024

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Statement of unaudited standalone financial results for the quarter ended 30 June 2024**

*(Amount in INR crores)*

Particulars	Quarter ended			Year ended
	30 June 2024	31 March 2024 (refer Note 7)	30 June 2023	31 March 2024
	(Unaudited)			(Audited)
<b>1 Income</b>				
Revenue from operations	565.62	545.56	457.23	2,036.50
Other income (refer note 5)	5,619.51	3.72	11.49	49.02
<b>Total income</b>	<b>6,185.13</b>	<b>549.28</b>	<b>468.72</b>	<b>2,085.52</b>
<b>2 Expenses</b>				
Purchase of medicines and consumables	113.12	107.86	101.62	418.10
Changes in inventories	(0.79)	(1.10)	(5.79)	(9.27)
Professional fees to consultant doctors	129.49	128.05	104.49	470.38
Laboratory outsourcing charges	17.41	19.12	14.59	68.16
Employee benefits expenses	96.22	77.85	72.33	318.36
Finance costs	21.43	20.92	15.64	78.37
Depreciation and amortisation expenses	34.64	35.65	26.05	121.38
Other expenses	108.82	114.28	86.97	410.69
<b>Total expenses</b>	<b>520.34</b>	<b>502.63</b>	<b>415.90</b>	<b>1,876.17</b>
<b>3 Profit before exceptional items and tax (1-2)</b>	<b>5,664.79</b>	<b>46.65</b>	<b>52.82</b>	<b>209.35</b>
<b>4 Exceptional items (refer note 5)</b>	372.70	-	-	-
<b>5 Profit before tax (3+4)</b>	<b>6,037.49</b>	<b>46.65</b>	<b>52.82</b>	<b>209.35</b>
<b>6 Tax expense / (benefit)</b>				
Current tax	21.85	(23.05)	-	-
Deferred tax	7.40	77.81	-	52.39
<b>Total tax expense / (benefit)</b>	<b>29.25</b>	<b>54.76</b>	<b>-</b>	<b>52.39</b>
<b>7 Profit/(loss) for the period / year (5-6)</b>	<b>6,008.24</b>	<b>(8.11)</b>	<b>52.82</b>	<b>156.96</b>
<b>8 Other comprehensive income for the period / year</b>				
Remeasurement of net defined benefit liability	-	(0.85)	-	(0.85)
Income tax relating to items that will not be reclassified to profit or loss	-	0.21	-	0.21
<b>Other comprehensive income, net of taxes</b>	<b>-</b>	<b>(0.64)</b>	<b>-</b>	<b>(0.64)</b>
<b>9 Total comprehensive income/(loss) (7+8)</b>	<b>6,008.24</b>	<b>(8.75)</b>	<b>52.82</b>	<b>156.32</b>
<b>10 Paid-up equity share capital (Face value of INR 10 each)</b>	499.52	499.52	499.52	499.52
<b>11 Other equity</b>				2,794.72
<b>12 Earnings per share (Face value of INR 10 each)</b>				
Basic (in INR)	Not annualised 120.67	Not annualised (0.16)	Not annualised 1.06	Annualised 3.15
Diluted (in INR)	120.50	(0.16)	1.06	3.15

See accompanying notes to the statement of unaudited standalone financial results

**Aster DM Healthcare Limited**  
CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Notes to the statement of unaudited standalone financial results:**

- 1) The Statement of unaudited standalone financial results ('the Statement') of Aster DM Healthcare Limited ('the Company') which includes the ESOP Trust for the quarter ended 30 June 2024 has been reviewed by the Audit Committee and approved by the Board of Directors on 31 July 2024. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- 2) The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- 3) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the statement of unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in the statement of unaudited standalone financial results.
- 4) During the quarter ended 30 June 2024, the Nomination and Remuneration Committee of the Company approved the grant of 777,208 options (exercise price ranging from INR 10.00 to INR 263.00) to the employees of the Company under the Aster DM Healthcare Limited Employees Stock Option Plan 2013.
- 5) The Company concluded the separation of its Gulf Cooperation Council ('GCC') business on 03 April 2024. Pursuant to the sale of GCC business, the Company received INR 5,569.96 crores as dividend from Affinity Holdings Private Limited ("Affinity"), a subsidiary in Mauritius. Affinity also redeemed the preference shares held by the Company for an amount of INR 1,828.52 crores. The redemption of preference shares resulted in a gain of INR 372.70 crores for the Company. The same has been presented as 'exceptional item' in the Statement.

The Board of Directors at its meeting held on 12 April 2024 approved a special dividend of INR 118.00 per equity share. The same has been distributed to the shareholders of the Company post the approval of the Board of Directors of the Company.

- 6) During the quarter ended 30 June 2024, the Company entered into an Addendum Hospital Operation and Management Agreement with Cauvery Medical Centre Private Limited for the expansion of its existing Aster CMI Hospital premises, Bengaluru. The same was effective from 25 May 2024.
- 7) The figures for the quarter ended 31 March 2024 are balancing figures between audited figures in respect of year ended 31 March 2024 and the unaudited published figures in respect of nine months ended 31 December 2023 which were reviewed by the Statutory Auditors.
- 8) Statement of unaudited standalone financial results are available for perusal at the website of the Company and the stock exchanges.

*For and on behalf of the Board of Directors of*

**Aster DM Healthcare Limited**  
CIN : L85110KA2008PLC147259

MANDAYAPURA  
TH AZAD  
MOOPEN

Digitally signed by  
MANDAYAPURATH AZAD  
MOOPEN  
Date: 2024.07.31 18:18:52  
+05'30'

**Dr. Azad Moopen**  
*Chairman and Managing Director*  
DIN 00159403  
Calicut  
31 July 2024

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Aster DM Healthcare Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint venture for the quarter ended 30 June 2024 ("Statement") which includes the financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities as provided in Annexure 1.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Unaudited Consolidated Financial Results includes the interim financial information of 73 subsidiaries and ESOP trust which have not been reviewed by their auditors, whose interim financial information reflect total revenue of INR 184.17 crores for the quarter ended 30 June 2024, total profit after tax of INR 2.68 crores for the quarter ended 30 June 2024 and total comprehensive income of INR 2.68 crores for the quarter ended 30 June 2024, as considered in the Statement. The Unaudited Consolidated Financial Results also includes the Group's share of loss after tax of INR 2.71 crores for the quarter ended 30 June 2024 and total

# Deloitte Haskins & Sells

comprehensive loss of INR 2.71 crores for the quarter ended 30 June 2024, in respect of 8 associates and 1 joint venture based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration No. 008072S)

VIKAS  
BAGARIA  Digitally signed by  
VIKAS BAGARIA  
Date: 2024.07.31  
19:45:42 +05'30'

**Vikas Bagaria**  
Partner  
(Membership No. 60408)  
(UDIN: 24060408BKFSMK6864)

Place: Calicut, Kerala  
Date: 31 July 2024

# Deloitte Haskins & Sells

## Annexure 1 – List of entities consolidated

S.No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Subsidiary	India
3	Ambady Infrastructure Private Limited	Subsidiary	India
4	Aster DM Healthcare (Trivandrum) Private Limited	Subsidiary	India
5	Malabar Institute of Medical Sciences Limited	Subsidiary	India
6	Prerana Hospital Limited	Subsidiary	India
7	Sri Sainatha Multispeciality Hospitals Private Limited	Subsidiary	India
8	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
9	Aster Clinical Lab LLP	Subsidiary	India
10	Hindustan Pharma Distributors Private Limited	Subsidiary	India
11	Affinity Holdings Private Limited	Subsidiary	Mauritius
12	EMED Human Resources India Private Limited	Step down Subsidiary	India
13	Ezhimala Infrastructure LLP	Step down Subsidiary	India
14	Warseps Healthcare LLP	Step down Subsidiary	India
15	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
16	Aster Ramesh Duhita LLP	Step down Subsidiary	India
17	Komali Fertility Centre LLP (earlier Ramesh Fertility Centre LLP)	Step down Subsidiary	India
18	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
19	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
20	Cantown Infra Developers LLP	Step down Subsidiary	India
78	Aster Shared Services Centre Private Limited	Step down Subsidiary w.e.f. 8 November 2023	India
80	Aasraya Healthcare LLP	Step down Subsidiary w.e.f. 27 February 2024	India
21	Aster Caribbean Holdings Limited	Step down Subsidiary	Cayman Island*
22	Aster Cayman Hospital Limited	Step down Subsidiary	Cayman Island*
23	Aster DM Healthcare FZC	Step down Subsidiary	UAE*
24	Aster Hospital Sonapur L.L.C	Step down Subsidiary	UAE*
25	Radiant Healthcare L.L.C	Step down Subsidiary	UAE*
26	Aster Day Surgery Centre LLC	Step down Subsidiary	UAE*
27	DM Healthcare (L L C)	Step down Subsidiary	UAE*
28	Wahat Al Aman Home Health Care L.L.C.	Step down Subsidiary	UAE*
29	Aster Grace Nursing and Physiotherapy LLC	Step down Subsidiary	UAE*
30	Aster Pharmacies Group LLC	Step down Subsidiary	UAE*
31	New Aster Pharmacy DMCC	Step down Subsidiary	UAE*
32	Aster DCC Pharmacy LLC	Step down Subsidiary	UAE*
33	Aster Al Shafar Pharmacies Group LLC	Step down Subsidiary	UAE*
34	Rafa Pharmacy LLC	Step down Subsidiary	UAE*

# Deloitte Haskins & Sells

S.No	Entity	Relationship	Country of incorporation
35	Aster Pharmacy LLC, AUH	Step down Subsidiary	UAE*
36	Med Shop Drugs Store LLC	Step down Subsidiary	UAE*
37	Alfa Drug Store LLC	Step down Subsidiary	UAE*
38	Alfa One Drug Store LLC	Step down Subsidiary	UAE*
39	Alfaone FZ-LLC	Step down Subsidiary	UAE*
40	DM Pharmacies LLC **	Step down Subsidiary	UAE*
41	Aster Opticals LLC	Step down Subsidiary	UAE*
42	Medcare Hospital (L.L.C)	Step down Subsidiary	UAE*
43	Premium Healthcare Limited	Step down Subsidiary	UAE*
44	Dr. Moopens Healthcare Management Services LLC	Step down Subsidiary	UAE*
45	Eurohealth Systems FZ LLC	Step down Subsidiary	UAE*
46	Al Rafa Investments Limited	Step down Subsidiary	UAE*
47	Al Rafa Holdings Limited	Step down Subsidiary	UAE*
48	Alfa Investments Limited #	Step down Subsidiary	UAE*
49	Active Holdings Limited	Step down Subsidiary	UAE*
50	Al Rafa Medical Centre LLC	Step down Subsidiary	UAE*
51	Dar Al Shifa Medical Centre LLC	Step down Subsidiary	UAE*
52	Aster Primary Care LLC	Step down Subsidiary	UAE*
53	Modern Dar Al Shifa Pharmacy LLC	Step down Subsidiary	UAE*
54	Harley Street LLC	Step down Subsidiary	UAE*
55	Harley Street Pharmacy LLC	Step down Subsidiary	UAE*
56	Harley Street Medical Centre LLC	Step down Subsidiary	UAE*
57	Harley Street Dental LLC	Step down Subsidiary	UAE*
58	Grand Optics LLC	Step down Subsidiary	UAE*
59	Zahrat Al Shefa Medical Center L.L.C	Step down Subsidiary	UAE*
60	Samary Pharmacy LLC	Step down Subsidiary	UAE*
61	Metro Meds Pharmacy L.L.C	Step down Subsidiary	UAE*
62	Metro Medical Center L.L.C	Step down Subsidiary	UAE*
63	Symphony Healthcare Management Services LLC	Step down Subsidiary	UAE*
64	E-Care International Medical Billing Services Co. LLC	Step down Subsidiary	UAE*
74	Al Shafar Pharmacy LLC, AUH **	Step down Subsidiary	UAE*
75	Aster Medical Centre LLC**	Step down Subsidiary	UAE*
76	Zest Wellness Pharmacy LLC	Step down Subsidiary	UAE*
77	Skin III Ltd	Step down Subsidiary	UAE*
79	Lunettes (House of Quality Optics) LLC	Step down Subsidiary w.e.f 1 January 2024	UAE*
65	Al Raffah Hospital LLC	Step down Subsidiary	Oman*
66	Al Raffah Pharmacies Group LLC	Step down Subsidiary	Oman*
67	Oman Al Khair Hospital L.L.C	Step down Subsidiary	Oman*
68	Dr. Moopen's Healthcare Management Services WLL	Step down Subsidiary	Qatar*

# Deloitte Haskins & Sells

S.No	Entity	Relationship	Country of incorporation
69	Welcare Polyclinic W.L.L	Step down Subsidiary	Qatar*
70	Dr. Moopens Aster Hospital WLL	Step down Subsidiary	Qatar*
71	Sanad Al Rahma for Medical Care LLC	Step down Subsidiary	Kingdom of Saudi Arabia*
72	Aster DM Healthcare WLL (earlier Aster DM Healthcare SPC)	Step down Subsidiary	Bahrain*
73	Orange Pharmacies LLC	Step down Subsidiary	Jordan*
81	MIMS Infrastructure and Properties Private Limited	Associates	India
82	Alfaone Medicals Private Limited	Associates	India
83	Alfaone Retail Pharmacies Private Limited	Associates	India
84	Mindriot Research and Innovation Foundation	Associates	India
85	Aries Holdings FZC	Associates	India
86	AAQ Healthcare Investments LLC	Associates	UAE*
87	Aries Investments LLC	Associates	UAE*
88	Al Mutamaizah Medcare Healthcare Investment Co. LLC	Associates	UAE*
89	Aster Arabia trading Company	Joint Venture	UAE*
90	DM Healthcare Employees Welfare Trust	Trust	India

\* has been disposed off as discontinued operations.

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

Statement of unaudited consolidated financial results for the quarter ended 30 June 2024

(Amount in INR crores)

Particulars	Quarter ended			Year ended
	30 June 2024	31 March 2024 (refer Note 6)	30 June 2023	31 March 2024
	(Unaudited)			(Audited)
<b><u>Continuing Operations</u></b>				
<b>1 Income</b>				
Revenue from operations	1,001.87	973.59	841.21	3,698.90
Other income	48.72	4.08	7.79	24.85
<b>Total income</b>	<b>1,050.59</b>	<b>977.67</b>	<b>849.00</b>	<b>3,723.75</b>
<b>2 Expenses</b>				
Purchase of medicines and consumables	225.29	230.01	221.65	927.50
Changes in inventories	3.32	1.79	(2.98)	(11.63)
Professional fees to consultant doctors	225.91	220.10	184.27	815.62
Laboratory outsourcing charges	5.60	6.20	7.46	24.07
Employee benefits expense	190.44	170.89	155.66	675.93
Finance costs	29.15	29.88	24.97	110.30
Depreciation and amortisation expenses	60.41	58.36	50.68	219.97
Other expenses	187.77	185.26	153.23	689.46
<b>Total expenses</b>	<b>927.89</b>	<b>902.49</b>	<b>794.94</b>	<b>3,451.22</b>
<b>3 Profit before share of profit/(loss) of equity accounted investees and tax (1-2)</b>	<b>122.70</b>	<b>75.18</b>	<b>54.06</b>	<b>272.53</b>
<b>4 Share of loss of equity accounted investees</b>	<b>(2.71)</b>	<b>(2.86)</b>	<b>(3.06)</b>	<b>(11.34)</b>
<b>5 Profit before tax (3+4)</b>	<b>119.99</b>	<b>72.32</b>	<b>51.00</b>	<b>261.19</b>
<b>6 Tax expense</b>				
Current tax	30.43	(15.55)	5.66	33.33
Current tax for earlier years	-	(0.76)	-	(0.93)
Deferred tax	8.56	46.88	0.66	24.11
<b>Total tax expense</b>	<b>38.99</b>	<b>30.57</b>	<b>6.32</b>	<b>56.51</b>
<b>7 Profit for the period/ year from continuing operations (5-6)</b>	<b>81.00</b>	<b>41.75</b>	<b>44.68</b>	<b>204.68</b>
<b>8 Discontinued operations</b>				
(a) Profit/ (loss) before tax from discontinued operations (Refer Note 4)	(76.89)	(43.56)	22.25	69.11
(b) Tax expense of discontinued operations	-	(0.36)	(47.08)	(62.23)
(c) Gain on disposal of business operations	5,148.09	-	-	-
<b>Profit/ (loss) after tax from discontinued operations</b>	<b>5,071.20</b>	<b>(43.92)</b>	<b>(24.83)</b>	<b>6.88</b>
<b>9 Profit/(loss) for the period/ year (7+8)</b>	<b>5,152.20</b>	<b>(2.17)</b>	<b>19.85</b>	<b>211.56</b>
<b>10 Other comprehensive income/ (loss) for the period/ year</b>				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of net defined benefit liability	-	13.89	-	13.89
Income tax on items that will not be reclassified subsequently to profit or loss	-	(1.48)	-	(1.48)
<i>Items that will be reclassified subsequently to profit or loss</i>				
Exchange difference in translating financial statements of foreign operations	0.02	5.55	(3.87)	44.22
Income tax on items that will be reclassified subsequently to profit or loss	-	3.30	1.21	(10.21)
<b>Other comprehensive income/ (loss), net of taxes</b>	<b>0.02</b>	<b>21.26</b>	<b>(2.66)</b>	<b>46.42</b>
<b>11 Total comprehensive income/ (loss) (9+10)</b>	<b>5,152.22</b>	<b>19.09</b>	<b>17.19</b>	<b>257.98</b>
<b>12 Profit attributable to :</b>				
Owners of the Company	5,145.18	(24.03)	4.90	129.28
Non-controlling interests	7.02	21.86	14.95	82.28
<b>Profit for the period/ year</b>	<b>5,152.20</b>	<b>(2.17)</b>	<b>19.85</b>	<b>211.56</b>
<b>13 Other comprehensive income/ (loss) attributable to :</b>				
Owners of the Company	0.02	20.91	(2.32)	42.61
Non-controlling interests	-	0.35	(0.34)	3.81
<b>Other comprehensive income/ (loss) for the period/ year</b>	<b>0.02</b>	<b>21.26</b>	<b>(2.66)</b>	<b>46.42</b>
<b>14 Total comprehensive income attributable to :</b>				
Owners of the Company	5,145.20	(3.12)	2.58	171.89
Non-controlling interests	7.02	22.21	14.61	86.09
<b>Total comprehensive income for the period/ year</b>	<b>5,152.22</b>	<b>19.09</b>	<b>17.19</b>	<b>257.98</b>
<b>15 Paid-up equity share capital (Face value of INR 10 each)</b>	<b>499.52</b>	<b>499.52</b>	<b>499.52</b>	<b>499.52</b>
<b>16 Other equity</b>				<b>4,060.27</b>
<b>17 Earnings per share (Face value of INR 10 each) from</b>				
<b>Continuing operations (INR)</b>				
Basic	1.49	0.66	0.82	3.60
Diluted	1.48	0.66	0.82	3.60
<b>Discontinued Operations (INR)</b>				
Basic	101.85	(1.14)	(0.72)	(1.00)
Diluted	101.71	(1.14)	(0.72)	(1.00)
<b>Continuing &amp; Discontinued Operations (INR)</b>				
Basic	103.34	(0.48)	0.10	2.60
Diluted	103.19	(0.48)	0.10	2.60

See accompanying notes to the statement of unaudited consolidated financial results

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Segment details of unaudited consolidated financial results for the quarter ended 30 June 2024**

(Amount in INR crores)

	Particulars	Quarter ended			Year ended
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		(Unaudited)			(Audited)
1	<b>Segment revenue</b>				
	Hospitals	1,004.14	2,111.80	1,877.84	8,104.59
	Clinics	30.36	728.38	603.52	2,681.06
	Retail Pharmacies (including opticals)	49.22	870.35	724.55	3,143.02
	Others	2.03	25.03	9.46	49.50
	<b>Total</b>	<b>1,085.75</b>	<b>3,735.56</b>	<b>3,215.37</b>	<b>13,978.17</b>
2	<b>Segment results before tax and interest</b>				
	Hospitals	150.16	260.80	183.01	914.65
	Clinics	(0.29)	77.77	52.23	271.03
	Retail Pharmacies (including opticals)	(7.61)	89.41	43.78	267.79
	Others	(4.86)	0.07	0.48	0.32
	<b>Total</b>	<b>137.40</b>	<b>428.05</b>	<b>279.50</b>	<b>1,453.79</b>
	<b>Adjustment :</b>				
	Finance cost	(32.30)	(111.29)	(98.89)	(410.76)
	Share of (loss) of equity accounted investees	(2.71)	(5.16)	(7.31)	(28.22)
	Other unallocable expenditure net of unallocable income	(59.29)	(282.83)	(100.05)	(684.49)
	Gain on disposal of business operations	5,148.09	-	-	-
	<b>Profit before tax from Continuing and Discontinued Operations</b>	<b>5,191.19</b>	<b>28.77</b>	<b>73.25</b>	<b>330.32</b>
3	<b>Segment assets</b>				
	Hospitals	4,583.34	10,526.69	9,565.20	10,526.69
	Clinics	12.19	2,342.18	2,434.69	2,342.18
	Retail Pharmacies (including opticals)	62.78	2,571.23	2,299.08	2,571.23
	Others	31.45	28.65	23.12	28.65
	Unallocated	1,753.19	2,522.56	860.79	2,522.56
	<b>Total</b>	<b>6,442.95</b>	<b>17,991.31</b>	<b>15,182.88</b>	<b>17,991.31</b>
4	<b>Segment liabilities</b>				
	Hospitals	2,453.17	6,303.70	5,828.84	6,303.70
	Clinics	29.77	1,457.68	1,257.36	1,457.68
	Retail Pharmacies (including opticals)	33.04	1,629.71	1,393.09	1,629.71
	Unallocated	332.21	3,570.11	1,847.47	3,570.11
	<b>Total</b>	<b>2,848.19</b>	<b>12,961.20</b>	<b>10,326.76</b>	<b>12,961.20</b>

See accompanying notes to the statement of unaudited consolidated financial results

**Notes to the statement of unaudited consolidated financial results for the quarter ended 30 June 2024:**

- 1) The statement of unaudited consolidated financial results ('the Statement') of Aster DM Healthcare Limited ('the Parent/ Company') and its subsidiaries (together referred to as 'the Group'), ESOP trust and its share of loss in associates and joint venture for the quarter ended 30 June 2024 has been reviewed by the Audit Committee and approved by the Board of Directors on 31 July 2024. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- 2) The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- 3) During the quarter ended 30 June 2024, the Nomination and Remuneration Committee of the Company approved the grant of 777,208 options (exercise price ranging from INR 10.00 to INR 263.00) to the employees of the Company under the Aster DM Healthcare Limited Employees Stock Option Plan 2013.

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

- 4) The Group announced the completion of the separation of its Gulf Cooperation Council ('GCC') business on 03 April 2024. As a result, the Company has classified the GCC business as Discontinued Operations in the Statement. The prior period amounts have been accordingly re-presented. Discontinued Operations include direct expenses, including transaction cost, clearly identifiable to the businesses being discontinued.

The impact of discontinued operations on income, expenses and tax is as under:

Particulars	Quarter ended			Year ended
	30 June 2024	31 March 2024 (refer Note 6)	30 June 2023	31 March 2024
		(Unaudited)		(Audited)
<b>Income</b>				
Revenue from operations	83.88	2,758.06	2,374.16	10,279.27
Other income	-	24.46	1.41	29.41
<b>Total income</b>	<b>83.88</b>	<b>2,782.52</b>	<b>2,375.57</b>	<b>10,308.68</b>
<b>Expenses</b>				
Purchase of medicines and consumables	26.65	939.30	854.00	3,485.92
Changes in inventories	-	(80.01)	(107.18)	(314.26)
Professional fees to consultant doctors	11.61	117.72	102.72	436.63
Laboratory outsourcing charges	-	11.26	11.49	53.91
Employee benefits expense	40.41	1,010.06	935.14	3,887.85
Finance costs	3.15	81.41	73.92	300.46
Depreciation and amortisation expenses	5.84	253.22	166.78	767.78
Other expenses	73.11	490.81	312.20	1,549.78
<b>Total expenses</b>	<b>160.77</b>	<b>2,823.77</b>	<b>2,349.07</b>	<b>10,168.07</b>
<b>Profit/(loss) before share of profit of equity accounted investees and tax</b>	<b>(76.89)</b>	<b>(41.25)</b>	<b>26.50</b>	<b>140.61</b>
Share of loss of equity accounted investees	-	(2.31)	(4.25)	(16.88)
Exceptional items	-	-	-	(54.62)
<b>Profit/(loss) before tax</b>	<b>(76.89)</b>	<b>(43.56)</b>	<b>22.25</b>	<b>69.11</b>
<b>Tax expense</b>				
Current tax	-	12.87	0.74	30.53
Current tax for earlier years	-	0.01	(1.03)	3.56
Deferred tax	-	(12.52)	47.37	28.14
<b>Total tax expense</b>	<b>-</b>	<b>0.36</b>	<b>47.08</b>	<b>62.23</b>
<b>Profit/(loss) for the period/ year from discontinued operations</b>	<b>(76.89)</b>	<b>(43.92)</b>	<b>(24.83)</b>	<b>6.88</b>

- 5) During the quarter ended 30 June 2024, the Group entered into an Addendum Hospital Operation and Management Agreement with Cauvery Medical Centre Private Limited for the expansion of its existing Aster CMI Hospital premises, Bengaluru. The same was effective from 25 May 2024.
- 6) The figures for the quarters ended 31 March 2024 are balancing figures between the audited figures in respect of year ended 31 March 2024, and the unaudited published figures in respect of nine months ended 31 December 2023, which were reviewed by the Statutory Auditors.
- 7) Statements of unaudited standalone and consolidated financial results are available for perusal at the website of the Company and the stock exchanges.

*For and on behalf of the Board of Directors of*

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

MANDAYAPURAT  
H AZAD MOOPEN  
Date: 2024.07.31 18:19:36  
+05'30'

**Dr. Azad Moopen**

*Chairman and Managing Director*

DIN 00159403

Calicut

31 July 2024

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Annexure A to statement of unaudited consolidated financial results for the quarter ended 30 June 2024**

SI No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Subsidiary	India
3	Ambady Infrastructure Private Limited	Subsidiary	India
4	Aster DM Healthcare (Trivandrum) Private Limited	Subsidiary	India
5	Malabar Institute of Medical Sciences Limited	Subsidiary	India
6	Prerana Hospital Limited	Subsidiary	India
7	Sri Sainatha Multispeciality Hospitals Private Limited	Subsidiary	India
8	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
9	Aster Clinical Lab LLP	Subsidiary	India
10	Hindustan Pharma Distributors Private Limited	Subsidiary	India
11	EMED Human Resources India Private Limited	Step down Subsidiary	India
12	Ezhimala Infrastructure LLP	Step down Subsidiary	India
13	Warseps Healthcare LLP	Step down Subsidiary	India
14	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
15	Aster Ramesh Duhita LLP	Step down Subsidiary	India
16	Komali Fertility Centre LLP (earlier Ramesh Fertility Centre LLP)	Step down Subsidiary	India
17	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
18	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
19	Cantown Infra Developers LLP	Step down Subsidiary	India
20	Aster Shared Services Centre Private Limited	Step down Subsidiary w.e.f. 8 November 2023	India*
21	Aasraya Healthcare LLP	Step down Subsidiary w.e.f. 27 February 2024	India
22	DM Healthcare Employees Welfare Trust	Trust	India
23	MIMS Infrastructure and Properties Private Limited	Associates	India
24	Alfaone Medicals Private Limited	Associates	India
25	Alfaone Retail Pharmacies Private Limited	Associates	India
26	Mindriot Research and Innovation Foundation	Associates	India
27	Affinity Holdings Private Limited	Subsidiary	Mauritius
28	Aster Caribbean Holdings Limited	Step down Subsidiary	Cayman Island*
29	Aster Cayman Hospital Limited	Step down Subsidiary	Cayman Island*
30	Aster DM Healthcare FZC	Step down Subsidiary	UAE*
31	Aster Hospital Sonapur L.L.C	Step down Subsidiary	UAE*
32	Radiant Healthcare L.L.C	Step down Subsidiary	UAE*
33	Aster Day Surgery Centre LLC	Step down Subsidiary	UAE*
34	DM Healthcare (L L C)	Step down Subsidiary	UAE*
35	Wahat Al Aman Home Health Care L.L.C.	Step down Subsidiary	UAE*
36	Aster Grace Nursing and Physiotherapy LLC	Step down Subsidiary	UAE*
37	Aster Pharmacies Group LLC	Step down Subsidiary	UAE*
38	New Aster Pharmacy DMCC	Step down Subsidiary	UAE*
39	Aster DCC Pharmacy LLC	Step down Subsidiary	UAE*
40	Aster Al Shafar Pharmacies Group LLC	Step down Subsidiary	UAE*
41	Rafa Pharmacy LLC	Step down Subsidiary	UAE*
42	Aster Pharmacy LLC, AUH	Step down Subsidiary	UAE*
43	Med Shop Drugs Store LLC	Step down Subsidiary	UAE*
44	Alfa Drug Store LLC	Step down Subsidiary	UAE*
45	Alfa One Drug Store LLC	Step down Subsidiary	UAE*
46	Alfaone FZ-LLC	Step down Subsidiary	UAE*
47	DM Pharmacies LLC **	Step down Subsidiary	UAE*
48	Aster Opticals LLC	Step down Subsidiary	UAE*
49	Medcare Hospital (L.L.C)	Step down Subsidiary	UAE*
50	Premium Healthcare Limited	Step down Subsidiary	UAE*
51	Dr. Moopens Healthcare Management Services LLC	Step down Subsidiary	UAE*
52	Eurohealth Systems FZ LLC	Step down Subsidiary	UAE*
53	Al Rafa Investments Limited	Step down Subsidiary	UAE*
54	Al Rafa Holdings Limited	Step down Subsidiary	UAE*
55	Alfa Investments Limited #	Step down Subsidiary	UAE*
56	Active Holdings Limited	Step down Subsidiary	UAE*
57	Al Rafa Medical Centre LLC	Step down Subsidiary	UAE*
58	Dar Al Shifa Medical Centre LLC	Step down Subsidiary	UAE*
59	Aster Primary Care LLC	Step down Subsidiary	UAE*
60	Modern Dar Al Shifa Pharmacy LLC	Step down Subsidiary	UAE*
61	Harley Street LLC	Step down Subsidiary	UAE*
62	Harley Street Pharmacy LLC	Step down Subsidiary	UAE*
63	Harley Street Medical Centre LLC	Step down Subsidiary	UAE*
64	Harley Street Dental LLC	Step down Subsidiary	UAE*
65	Grand Optics LLC	Step down Subsidiary	UAE*
66	Zahrat Al Shefa Medical Center L.L.C	Step down Subsidiary	UAE*
67	Samary Pharmacy LLC	Step down Subsidiary	UAE*
68	Metro Meds Pharmacy L.L.C	Step down Subsidiary	UAE*
69	Metro Medical Center L.L.C	Step down Subsidiary	UAE*
70	Symphony Healthcare Management Services LLC	Step down Subsidiary	UAE*
71	E-Care International Medical Billing Services Co. LLC	Step down Subsidiary	UAE*

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Annexure A to statement of consolidated financial results for the quarter and year ended 31 March 2024 (Continued)**

SI No	Entity	Relationship	Country of incorporation
72	Al Raffah Hospital LLC	Step down Subsidiary	Oman*
73	Al Raffah Pharmacies Group LLC	Step down Subsidiary	Oman*
74	Oman Al Khair Hospital L.L.C	Step down Subsidiary	Oman*
75	Dr. Moopen's Healthcare Management Services WLL	Step down Subsidiary	Qatar*
76	Welcare Polyclinic W.L.L	Step down Subsidiary	Qatar*
77	Dr. Moopens Aster Hospital WLL	Step down Subsidiary	Qatar*
78	Sanad Al Rahma for Medical Care LLC	Step down Subsidiary	Kingdom of Saudi Arabia*
79	Aster DM Healthcare WLL (earlier Aster DM Healthcare SPC)	Step down Subsidiary	Bahrain*
80	Orange Pharmacies LLC	Step down Subsidiary	Jordan*
81	Al Shafar Pharmacy LLC, AUH **	Step down Subsidiary	UAE*
82	Aster Medical Centre LLC**	Step down Subsidiary	UAE*
83	Zest Wellness Pharmacy LLC	Step down Subsidiary	UAE*
84	Skin III Ltd	Associate till 31 July 2023, Step down subsidiary w.e.f 1 August 2023	UAE*
85	Lunettes (House of Quality Optics) LLC	Step down Subsidiary w.e.f 1 January 2024	UAE*
86	Aries Holdings FZC	Associates	UAE*
87	AAQ Healthcare Investments LLC	Associates	UAE*
88	Aries Investments LLC	Associates	UAE*
89	Al Mutamaizah Medcare Healthcare Investment Co. LLC	Associates	UAE*
90	Aster Arabia trading Company	Joint Venture	KSA*

The principal place of business of all the entities listed above is the same as their respective countries of incorporation.

\* has been disposed off as discontinued operations. Please refer note 4 for further information

\*\* represents subsidiaries which are in the process of being wound-up.

# Although the percentage of voting rights as a result of legal holding by the Group is Nil, the Group has the power to appoint/replace all members of the Board of Directors. Consequently Group has control over the entity.

**Annexure-II**

**A. Details of Mr. Maniedath Madhavan Nambiar (DIN: 01122411) (Non-Executive Independent Director) and Mr. Sunil Theckath Vasudevan (DIN: 00294130) (Non-Executive Independent Director)**

Name of the Director	Mr. Maniedath Madhavan Nambiar (DIN: 01122411)	Mr. Sunil Theckath Vasudevan (DIN: 00294130)
Reason for change	Appointment	Appointment
Date of Appointment & term of appointment	July 31, 2024  Mr. Maniedath Madhavan Nambiar (DIN: 01122411) has been appointed as an Additional Director (Non-Executive Independent) subject to approval of the shareholders with effect from July 31, 2024, till the conclusion of 19 <sup>th</sup> Annual General Meeting of the Company to be held in the year 2027	July 31, 2024  Mr. Sunil Theckath Vasudevan (DIN: 00294130) has been appointed as an Additional Director (Non-Executive Independent) subject to approval of the shareholders with effect from July 31, 2024 till the conclusion of 19 <sup>th</sup> Annual General Meeting of the Company to be held in the year 2027
Brief Profile	Attached as <b>Annexure III</b>	Attached as <b>Annexure III</b>
Disclosure of relationships between Directors	Mr. Maniedath Madhavan Nambiar is not related to any Director of the Company.	Mr. Sunil Theckath Vasudevan is not related to any Director of the Company.
Information as required pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018- 19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated June 20, 2018.	Mr. Maniedath Madhavan Nambiar is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.	Mr. Sunil Theckath Vasudevan is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

**Annexure-II**

**C. Details of Mr. Anoop Moopen (DIN: 02301362) (Non-Executive Non-Independent Director) and Dr. Zeba Azad Moopen (DIN: 03604401) (Non-Executive Non-Independent Director)**

Name of the Director	Mr. Anoop Moopen (DIN: 02301362)	Dr. Zeba Azad Moopen (DIN: 03604401)
Reason for change	Appointment	Appointment
Date of Appointment & term of appointment	July 31, 2024  Mr. Anoop Moopen (DIN: 02301362) will hold office as an Additional Director (Non-Executive and Non-Independent) upto the next Annual General Meeting of the Company, and thereafter, subject to the approval of the Members of the Company, as a Non-Executive and Non-Independent Director, liable to retire by rotation.	July 31, 2024  Dr. Zeba Azad Moopen (DIN: 03604401) will hold office as an Additional Director upto the next Annual General Meeting of the Company, and thereafter, subject to the approval of the Members of the Company, as a Non-Executive and Non-Independent Director, liable to retire by rotation.
Brief Profile	Attached as <b>Annexure III</b>	Attached as <b>Annexure III</b>
Disclosure of relationships between Directors	Mr. Anoop Moopen is not related to any Director of the Company.	Dr. Zeba Azad Moopen is not related to any Director of the Company except Dr. Azad Moopen (father) and Ms. Alisha Moopen (sister)
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018- 19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated June 20, 2018.	Mr. Anoop Moopen is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.	Dr. Zeba Azad Moopen is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

### Annexure III

#### A. Details of Mr. Maniedath Madhavan Nambiar (DIN: 01122411) (Non-Executive Independent Director)



**Mr. Maniedath Madhavan Nambiar**

Mr. Maniedath Madhavan Nambiar specializes in the policy and practice of infrastructure development innovation ecosystems for emerging technologies and industries and the design and management of Government-Industry partnerships.

His 36 years record of Public Service as an Officer of the Indian Administrative Service culminating in his appointment as Secretary to the Government of India at the Ministry of Civil Aviation has seen policy programme and regulatory work across key infrastructure and industrial sectors following his tenure in public service Mr. Nambiar's work in the private sector has focused on strengthening enterprise governance in technology finance healthcare and aviation sectors.

As Secretary, Civil Aviation, Mr. Nambiar led the redevelopment of India's largest airports at Delhi and Mumbai in doing so he directed the design and deployment of some of India's largest public- private infrastructure projects. He helped in formulating and establishing the national policy standard as Chairman and Managing Director (CMD) of Tamil Nadu State Government's apex industrial development agency. Mr. Nambiar conceptualized and commissioned the State's first public private toll road project information technology park and biotechnology park.

Mr. Maniedath Madhavan Nambiar has also developed policy ecosystems for innovation in emerging technologies and industries. At the Department of Information Technology Government of India he led the formulation of India's first Semiconductor Policy (and accompanying programmes) Policy Development for Electronics Hardware Manufacturing the reworking of National Law and Regulation to facilitate a growing IT industry and the establishment of India's first National Cyber Security and Emergency Response Agency (CERT-IN).

Mr. Maniedath Madhavan Nambiar is the Advisor to Executive Chairman Tata Sons. As Chairman of the Indian Institute of Information Technology and Management-Kerala IIITM-K, he has helped establish the Institute's Advanced Electronics Manufacturing Start-Up Incubator 'Maker Village'. He is an Independent Director of Tamil Nadu Industrial Development Corporation (TIDCO). He has also

# Aster

We'll Treat You Well



served as the Director in Rediff, Loyal Textiles Limited and Kannur International Airport Limited.

He taught public policy for several years at the School of International Public Affairs (SIPA), Columbia University. He was also a Fellow at the Judge Business School's Entrepreneurship Centre at the University of Cambridge. He is a Member of the Advisory Board at the School of Systems and Enterprises at the Stevens Institute of Technology, New Jersey.

Mr. Maniedath Madhavan Nambiar holds a Master's Degree in Business Administration from the Faculty of Management Studies Delhi and a Bachelor's Degree in Economics from Loyola College, Madras University.

**Aster DM Healthcare Limited - Registered & Corporate Office**

CIN-L85110KA2008PLC147259

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,  
Mission Road, Sampangi Rama Nagar, Bengaluru, Karnataka 560027

**T** : +91 484 669 9999

**E** : [info@asterdmhealthcare.com](mailto:info@asterdmhealthcare.com)  
[www.asterdmhealthcare.in](http://www.asterdmhealthcare.in)

### Annexure-III

#### B. Details of Mr. Sunil Theckath Vasudevan (DIN: 00294130) (Non-Executive Independent Director)



#### Mr. Sunil Theckath Vasudevan

Mr. Sunil Theckath Vasudevan is a Co-Founder and Partner at Amicus Capital, an India-dedicated growth capital firm with assets under management of \$260 million. He has over 33 years of work experience, of which 30 years has been in private equity.

Prior to Amicus Capital, Mr. Sunil Theckath Vasudevan was a co-founding General Partner at True North between 2000 and 2013, a pioneering firm in mid-market buy-outs in India. During his tenure at True North, the firm raised four funds totalling to approximately \$1.17 billion and grew to be one of the largest India-dedicated private equity firms. He was instrumental in defining the portfolio strategy and setting-up the investment processes at True North. He also established the Bangalore office of True North in 2001 and led True North's investments in the healthcare sector. He made several successful investments like Biocon, Trinethra Supermarkets, etc. He served on the Board of directors of several companies including Trinethra Superretail Private Limited, Robo Silicon Private Limited and Music Broadcast Limited (Radio City) and RDC Concrete (India) Private Limited.

During the period 1993-2000, Mr. Sunil Theckath Vasudevan was part of the investment team at ICICI Venture Funds Management Company Limited ("**ICICI Venture**"), one of the earliest venture capital and private equity firms in India. At ICICI Venture, he made investments in sectors such as engineering, business services and retailing.

Earlier, Mr. Sunil Theckath Vasudevan worked as an engineer at Larsen & Toubro Limited ("**L&T**"), India's largest private-sector engineering company (1988-1991). At L&T, he was part of the project execution team which executed large petrochemical and power projects.

Mr. Sunil Theckath Vasudevan is a graduate in Mechanical Engineering from the University of Kerala and a post-graduate in management from the Indian Institute of Management, Bangalore.

### Annexure-III

#### C. Details of Mr. Anoop Moopen (DIN: 02301362) (Non-Executive Non-Independent Director)



**Mr. Anoop Moopen**

An established business entrepreneur with a dynamic record of constant growth in changing markets and proven achievements in Civil Construction, Interior decoration, Facilities management, Fire-fighting services, Electro-mechanical services, High voltage & power distribution solutions and Trading, Mr. Anoop Moopen also holds a remarkable flair for leadership.

A graduate in Civil Engineering from Crescent College of Engineering, Chennai and a Masters in International Construction Management from Leeds University, London, he is currently Managing Director of Twelve companies – Aztec Middle East Contracting L.L.C (Dubai, Sharjah, Ajman, Ras Al Khaimah), Aztec Middle East Engineering & Contracting L.L.C (Abu Dhabi), Aztec Technical Services & Interior Decoration L.L.C (Dubai), Aesthetics Technical Solution L.L.C (Dubai), Snags Analytics L.L.C (Dubai), Aztec Prime Fire Protection L.L.C (Dubai), Oscar Oil Field Trading L.L.C (Abu Dhabi), Aztec Saudi Arabia Contracting & Construction Company LTD (KSA) and Moopen's Aztech L.L.P (India). He has also been the helm to the group's venture into the education sector and is the Managing Director of (WIMS) Wayanad Institute of Medical Sciences, India. He also presides as the Director of Horizon School, Calicut & Toddler Town British Nurseries, Dubai. A firm believer in the immeasurable value of quality healthcare services, Mr. Anoop Moopen was a Board member and Director at Aster DM Healthcare Limited, which manages and operates Medicare Hospitals and clinics, Aster Hospitals, Aster Clinics and Aster Pharmacies, whose branches exist in the U.A.E, Oman, Qatar, Saudi, Jordan, Philippines, Kuwait and India.

Beginning his illustrious career at Galfar Contratcing, Oman, as a Project Engineer in 1998, Mr. Anoop Moopen rose to become a Contracts Engineer at Wade Adams Contracting, Dubai, in 2001. Taking over the command of Al Turath Al Arabi Contracting LLC in 2003, founded by his father Mr. Ahmed Moopen, in 1993, Mr. Anoop Moopen firmly and single-handedly established it as a definitive Construction firm in the Gulf. He has since founded other companies in related fields and nearby geographies.

Mr. Anoop Moopen's ascent to success and his vast experience, interpersonal and business skills speaks volumes of his ability to strengthen any business he oversees. Apart from his obvious flair for leadership,

# Aster

We'll Treat You Well



Mr. Moopen's considerable skills include Operations Management, Acquisitions and Integrations, Engineering and Manufacturing, Strategic Partnerships and ensuring Customer Satisfaction and Allegiance.

Mr. Anoop Moopen served as a Non-executive Director on the board of Aster DM Healthcare Limited for a period of 15 years, from April 20, 2009 to August 14, 2024.

**Aster DM Healthcare Limited - Registered & Corporate Office**

CIN-L85110KA2008PLC147259

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,

Mission Road, Sampangi Rama Nagar, Bengaluru, Karnataka 560027

**T** : +91 484 669 9999

**E** : [info@asterdmhealthcare.com](mailto:info@asterdmhealthcare.com)

[www.asterdmhealthcare.in](http://www.asterdmhealthcare.in)

### Annexure-III

#### D. Details of Dr. Zeba Azad Moopen (DIN: 03604401) (Non-Executive Non-Independent Director)



Dr. Zeba Azad Moopen

Dr. Zeba Moopen, daughter of the renowned Dr. Azad Moopen, inspired by her father's pioneering vision has evolved from a promising medical aspirant to a leader now prepared to take on the responsibility of guiding Aster DM Healthcare, India towards its next milestone.

Her professional journey at Aster DM Healthcare Limited commenced in 2017, where she oversaw Orthopedic operations at Medcare, UAE, and played a crucial role in establishing Aster Volunteers, the Organisation's esteemed CSR initiative. As Director, she also played a key role in the evolution of Dr. Moopen's Medical College (formerly Wayanad Institute of Medical Sciences).

Between 2020-2022, Dr. Zeba played a pivotal role in setting up Aster Digital Health, redefining patient engagement and access through state-of-the-art digital solutions. She also spearheaded the inception of Wellth by Medcare, a premier centre for integrative medicine in the UAE. Dr. Zeba's commitment underscores her dedication to advancing healthcare through technological innovation, reinforcing Aster DM Healthcare's position at the forefront of global healthcare evolution.

Dr. Zeba's illustrious career is anchored by a distinguished academic foundation. She began her pre-medical studies at the prestigious University of Pennsylvania before earning her MBBS from KMC Manipal in 2015. Her medical expertise and understanding of healthcare operations were further refined through an internship at St. John's Hospital in 2016.

Dr. Zeba Moopen's achievements not only perpetuate the esteemed legacy of her family but also affirm her stature as a distinguished global leader in healthcare.

Outside her professional pursuits, Dr. Zeba is an Indian national record holder in freediving.